Immunogenicity, Safety and 1 Year Persistence of Antibodies After Either One or Two Doses of Meningococcal ACWY Conjugate Vaccine in Healthy Children 2 Through 10 Years of Age.

Exclusion criteria

• ✕. Unwilling or unable to give written informed assent or consent to participate in the study.
• ✕. Perceived to be unreliable or unavailable for the duration of the study period.
• ✕. Previous confirmed or suspected disease caused by N. meningitidis.
• ✕. Previously immunized with a meningococcal vaccine (licensed or investigational).
• ✕. Receipt of any investigational or non-registered product within 30 days prior to enrolment or who expect to receive an investigational drug or vaccine prior to the completion of the study.
• ✕. Receipt or plan to receive any vaccines within 30 days before and after administration of each dose of the study vaccine.
• ✕. Significant acute infection within the 7 days prior to enrolment or body temperature of 38°C or greater within 3 days prior to enrolment.
• ✕. Previous serious acute, chronic or progressive disease, epilepsy or any progressive neurological disease or history of Guillain-Barre syndrome.